-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

Benzinga·03/31/2026 13:45:26
Listen to the news
Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.